Clinical Trials for Prinicipal Investigator: Farshid Dayyani

5 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
SWOG-S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-Refractory Metastatic Colorectal Cancer (mCRC) Open
UCI-17-107 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Open
UCI-17-39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation Open
UCI-17-97 A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) Open
UCI-18-15 A Phase III, Randomized, Double-Blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab or Placebo as First-Line Treatment in Participants with HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) Open